US Congress House Bill 5894 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Democrat 4-0)
Status: Introduced on February 13 2020 - 25% progression, died in committee
Action: 2020-02-13 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]

Requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency. On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority.

Transparency in Prescription Drug Advertising Act

Rep. Sharice Davids [D-KS]

Rep. Elissa Slotkin [D-MI]

Rep. Abby Finkenauer [D-IA]

Rep. Ed Perlmutter [D-CO]

Date	Chamber	Action
2020-02-13	House	Referred to the House Committee on Energy and Commerce.
2020-02-13	House	Introduced in House

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/house-bill/5894/all-info
Text	https://www.congress.gov/116/bills/hr5894/BILLS-116hr5894ih.pdf